Pink Sheet Podcast: US FDA In A Biden Administration, Aducanumab’s Adcomm Failure
Pink Sheet reporters and editor discuss the potential changes at the FDA under President-elect Biden and the take-aways from the negative advisory committee recommendation for Biogen’s proposed Alzheimer’s drug aducanumab.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.